A Single Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of ILV-095 Administered Subcutaneously to Subjects With Psoriasis.
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2017
At a glance
- Drugs ILV 095 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Jul 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Jun 2011 Planned End Date changed from 1 Apr 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.